215 related articles for article (PubMed ID: 31896573)
21. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract][Full Text] [Related]
22. MELK expression correlates with tumor mitotic activity but is not required for cancer growth.
Giuliano CJ; Lin A; Smith JC; Palladino AC; Sheltzer JM
Elife; 2018 Feb; 7():. PubMed ID: 29417930
[TBL] [Abstract][Full Text] [Related]
23. Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells.
Kig C; Beullens M; Beke L; Van Eynde A; Linders JT; Brehmer D; Bollen M
J Biol Chem; 2013 Aug; 288(33):24200-12. PubMed ID: 23836907
[TBL] [Abstract][Full Text] [Related]
24. MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma.
Tang Q; Li W; Zheng X; Ren L; Liu J; Li S; Wang J; Du G
Signal Transduct Target Ther; 2020 Dec; 5(1):279. PubMed ID: 33262323
[TBL] [Abstract][Full Text] [Related]
25. Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.
Du T; Qu Y; Li J; Li H; Su L; Zhou Q; Yan M; Li C; Zhu Z; Liu B
Mol Cancer; 2014 May; 13():100. PubMed ID: 24885567
[TBL] [Abstract][Full Text] [Related]
26. MELK is not necessary for the proliferation of basal-like breast cancer cells.
Huang HT; Seo HS; Zhang T; Wang Y; Jiang B; Li Q; Buckley DL; Nabet B; Roberts JM; Paulk J; Dastjerdi S; Winter GE; McLauchlan H; Moran J; Bradner JE; Eck MJ; Dhe-Paganon S; Zhao JJ; Gray NS
Elife; 2017 Sep; 6():. PubMed ID: 28926338
[TBL] [Abstract][Full Text] [Related]
27. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
28. Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight.
Touré BB; Giraldes J; Smith T; Sprague ER; Wang Y; Mathieu S; Chen Z; Mishina Y; Feng Y; Yan-Neale Y; Shakya S; Chen D; Meyer M; Puleo D; Brazell JT; Straub C; Sage D; Wright K; Yuan Y; Chen X; Duca J; Kim S; Tian L; Martin E; Hurov K; Shao W
J Med Chem; 2016 May; 59(10):4711-23. PubMed ID: 27187609
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
30. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
[TBL] [Abstract][Full Text] [Related]
31. Maternal embryonic leucine zipper kinase is stabilized in mitosis by phosphorylation and is partially degraded upon mitotic exit.
Badouel C; Chartrain I; Blot J; Tassan JP
Exp Cell Res; 2010 Aug; 316(13):2166-73. PubMed ID: 20420823
[TBL] [Abstract][Full Text] [Related]
32. Cdk1 activity is required for mitotic activation of aurora A during G2/M transition of human cells.
Van Horn RD; Chu S; Fan L; Yin T; Du J; Beckmann R; Mader M; Zhu G; Toth J; Blanchard K; Ye XS
J Biol Chem; 2010 Jul; 285(28):21849-57. PubMed ID: 20444701
[TBL] [Abstract][Full Text] [Related]
33. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
[TBL] [Abstract][Full Text] [Related]
34. 5-Keto-3-cyano-2,4-diaminothiophenes as selective maternal embryonic leucine zipper kinase inhibitors.
Boutard N; Sabiniarz A; Czerwińska K; Jarosz M; Cierpich A; Kolasińska E; Wiklik K; Gluza K; Commandeur C; Buda A; Stasiowska A; Bobowska A; Galek M; Fabritius CH; Bugaj M; Palacz E; Mazan A; Zarębski A; Krawczyńska K; Żurawska M; Zawadzki P; Milik M; Węgrzyn P; Dobrzańska M; Brzózka K; Kowalczyk P
Bioorg Med Chem Lett; 2019 Feb; 29(4):607-613. PubMed ID: 30626559
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
36. Arrestin-3 interaction with maternal embryonic leucine-zipper kinase.
Perry NA; Fialkowski KP; Kaoud TS; Kaya AI; Chen AL; Taliaferro JM; Gurevich VV; Dalby KN; Iverson TM
Cell Signal; 2019 Nov; 63():109366. PubMed ID: 31352007
[TBL] [Abstract][Full Text] [Related]
37. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe.
Castedo M; Perfettini JL; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G
Oncogene; 2004 May; 23(25):4353-61. PubMed ID: 15048074
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
39. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML; Park JH; Nishidate T; Nakamura Y; Katagiri T
Breast Cancer Res; 2007; 9(1):R17. PubMed ID: 17280616
[TBL] [Abstract][Full Text] [Related]
40. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
